Zealand Pharma A/S (OTCMKTS:ZLDPF) vs. Pliant Therapeutics (NASDAQ:PLRX) Head to Head Survey

Pliant Therapeutics (NASDAQ:PLRX) and Zealand Pharma A/S (OTCMKTS:ZLDPF) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, valuation and risk.

Earnings and Valuation

This table compares Pliant Therapeutics and Zealand Pharma A/S”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pliant Therapeutics	$1.58 million	45.26	-$149.34 million	($1.49)	-0.78
Zealand Pharma A/S	$1.40 billion	2.59	$977.29 million	$6.03	8.38

Zealand Pharma A/S has higher revenue and earnings than Pliant Therapeutics. Pliant Therapeutics is trading at a lower price-to-earnings ratio than Zealand Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Pliant Therapeutics and Zealand Pharma A/S’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pliant Therapeutics	N/A	-52.17%	-40.46%
Zealand Pharma A/S	58.86%	18.53%	17.14%

Institutional & Insider Ownership

97.3% of Pliant Therapeutics shares are owned by institutional investors. 8.7% of Pliant Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Volatility & Risk

Pliant Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the S&P 500. Comparatively, Zealand Pharma A/S has a beta of 0.88, suggesting that its stock price is 12% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations for Pliant Therapeutics and Zealand Pharma A/S, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pliant Therapeutics	2	1	1	0	1.75
Zealand Pharma A/S	1	7	1	1	2.20

Pliant Therapeutics presently has a consensus price target of $3.00, suggesting a potential upside of 159.74%. Given Pliant Therapeutics’ higher possible upside, equities analysts clearly believe Pliant Therapeutics is more favorable than Zealand Pharma A/S.

Summary

Zealand Pharma A/S beats Pliant Therapeutics on 9 of the 14 factors compared between the two stocks.

About Pliant Therapeutics

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.